Bone marrow sarcoidosis in Takayasu arteritis: Case report and literature review. [PDF]
Fakih O +5 more
europepmc +1 more source
Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato +4 more
wiley +1 more source
Use of Two Biologics During Pregnancy: Infliximab and Vedolizumab: A Case Study. [PDF]
Hoekstra B +6 more
europepmc +1 more source
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
Ofir Elalouf, Ori Elkayam Department of Rheumatology, Sackler Faculty of Medicine, Tel Aviv Medical Center, Tel Aviv, Israel Abstract: The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS).
Elalouf O, Elkayam O
core
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Thomas Breakell +8 more
wiley +1 more source
Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study
No evidence of an increased risk of incident cancer or KC was observed with biologic versus non‐biologic systemic therapies or across the biologic classes evaluated. Abstract Background There are concerns that biologic therapies for psoriasis may increase cancer risk. Objectives To compare risks of (i) incident cancer excluding keratinocyte carcinomas (
Oras A. Alabas +9 more
wiley +1 more source
Infliximab Monotherapy as First-Line Treatment for Hepatic, Splenic, and Pulmonary Sarcoidosis in a Patient With High Cardiometabolic Risk. [PDF]
Coimbra M +4 more
europepmc +1 more source
ABSTRACT Background and Aim Risankizumab, a monoclonal interleukin 23p19 antibody, is a treatment for ulcerative colitis. This post hoc analysis reports the efficacy and safety of risankizumab for ulcerative colitis in patients in East Asia from the global phase 3 clinical trials. Methods In the 12‐week, phase 2b/3 induction study (NCT03398148), adults
Ken Takeuchi +14 more
wiley +1 more source
Miliary-Pattern Pulmonary Tuberculosis During Infliximab Therapy Despite Negative Tuberculosis Screening. [PDF]
Kenawi A +4 more
europepmc +1 more source
Successful bimekizumab retreatment after secondary failure in multi‐biologic‐resistant psoriasis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nicole Kah Mun Yoong +4 more
wiley +1 more source

